Osteoprotegerin Gene Polymorphisms Are Associated with Subclinical Atherosclerosis in the Mexican Mestizo Population

Overview

Journal Diagnostics (Basel)

Specialty Radiology

Date 2022 Jun 24

PMID 35741244

Authors

Benny Giovanni Cazarin-Santos

Nonanzit Perez-Hernandez

Rosalinda Posadas-Sanchez

Gilberto Vargas-Alarcon

Oscar Perez-Mendez

Juan Rodriguez-Silverio

Bladimir Roque-Ramirez

Veronica Marusa Borgonio-Cuadra

Jose Manuel Rodriguez-Perez

Affiliations

Soon will be listed here.

Abstract

Subclinical atherosclerosis (SA) is the presence of coronary calcification in the absence of cardiovascular symptoms, and it usually progresses to atherosclerotic disease. Studies have shown an association of osteoprotegerin gene (OPG) variants with calcification process in cardiovascular diseases; however, to this day there are no studies that evaluate individuals in the asymptomatic stage of atherosclerotic disease. Therefore, the purpose of this study was to analyze the association of four genetic variants and haplotypes of the OPG gene with the development of SA, through TaqMan genotyping assays. We also aimed to identify potential response elements for transcription factors in these genetic variants. The study included 1413 asymptomatic participants (1041 were controls and 372 were individuals with SA). The rs3102735 polymorphism appeared as a protective marker (OR = 0.693; 95% CI = 0.493−0.974; pheterozygote = 0.035; OR = 0.699; 95% CI = 0.496−0.985; pcodominant 1 = 0.040) and two haplotypes were associated with SA, one as a decreased risk: GACC (OR = 0.641, 95% CI = 0.414−0.990, p = 0.045) and another as an increased risk: GACT (OR = 1.208, 95% CI = 1.020−1.431, p = 0.029). Our data suggest a lower risk of SA in rs3102735 C carriers in a representative sample of Mexican mestizo population.

References

Faggiano A, Santangelo G, Carugo S, Pressman G, Picano E, Faggiano P . Cardiovascular Calcification as a Marker of Increased Cardiovascular Risk and a Surrogate for Subclinical Atherosclerosis: Role of Echocardiography. J Clin Med. 2021; 10(8). PMC: 8069968. DOI: 10.3390/jcm10081668. View

Posadas-Romero C, Lopez-Bautista F, Rodas-Diaz M, Posadas-Sanchez R, Kimura-Hayama E, Juarez-Rojas J . [Prevalence and extent of coronary artery calcification in an asymptomatic cardiovascular Mexican population: Genetics of Atherosclerotic Disease study]. Arch Cardiol Mex. 2017; 87(4):292-301. DOI: 10.1016/j.acmx.2016.12.004. View

Hernandez-Avila M, Romieu I, Parra S, Hernandez-Avila J, Madrigal H, Willett W . Validity and reproducibility of a food frequency questionnaire to assess dietary intake of women living in Mexico City. Salud Publica Mex. 1998; 40(2):133-40. DOI: 10.1590/s0036-36341998000200005. View

Strobescu-Ciobanu C, Giusca S, Caruntu I, Amalinei C, Rusu A, Cojocaru E . Osteopontin and osteoprotegerin in atherosclerotic plaque - are they significant markers of plaque vulnerability?. Rom J Morphol Embryol. 2021; 61(3):793-801. PMC: 8112796. DOI: 10.47162/RJME.61.3.17. View

Cottin Y, Issa R, Benalia M, Mouhat B, Meloux A, Tribouillard L . Association between Serum Osteoprotegerin Levels and Severity of Coronary Artery Disease in Patients with Acute Myocardial Infarction. J Clin Med. 2021; 10(19). PMC: 8509596. DOI: 10.3390/jcm10194326. View

Mautner G, Mautner S, Froehlich J, Feuerstein I, Proschan M, Roberts W . Coronary artery calcification: assessment with electron beam CT and histomorphometric correlation. Radiology. 1994; 192(3):619-23. DOI: 10.1148/radiology.192.3.8058924. View

Hakimi M, Hyhlik-Durr A, von Au A, Betz M, Demirel S, Dihlmann S . The expression of glycophorin A and osteoprotegerin is locally increased in carotid atherosclerotic lesions of symptomatic compared to asymptomatic patients. Int J Mol Med. 2013; 32(2):331-8. DOI: 10.3892/ijmm.2013.1401. View

Rochette L, Meloux A, Rigal E, Zeller M, Malka G, Cottin Y . The Role of Osteoprotegerin in Vascular Calcification and Bone Metabolism: The Basis for Developing New Therapeutics. Calcif Tissue Int. 2019; 105(3):239-251. DOI: 10.1007/s00223-019-00573-6. View

Gunes M, Temizkan S, Apaydin T, Ilgin C, Haklar G, Yavuz D . Serum osteoprotegerin levels, endothelial function and carotid intima-media thickness in type 2 diabetic patients. J Diabetes Complications. 2021; 35(12):108073. DOI: 10.1016/j.jdiacomp.2021.108073. View

10.

Dutka M, Bobinski R, Wojakowski W, Francuz T, Pajak C, Zimmer K . Osteoprotegerin and RANKL-RANK-OPG-TRAIL signalling axis in heart failure and other cardiovascular diseases. Heart Fail Rev. 2021; 27(4):1395-1411. PMC: 9197867. DOI: 10.1007/s10741-021-10153-2. View

11.

Makarovic S, Makarovic Z, Steiner R, Mihaljevic I, Milas-Ahic J . Osteoprotegerin and Vascular Calcification: Clinical and Prognostic Relevance. Coll Antropol. 2016; 39(2):461-8. View

12.

Juarez-Cedillo T, Zuniga J, Acuna-Alonzo V, Perez-Hernandez N, Rodriguez-Perez J, Barquera R . Genetic admixture and diversity estimations in the Mexican Mestizo population from Mexico City using 15 STR polymorphic markers. Forensic Sci Int Genet. 2008; 2(3):e37-9. DOI: 10.1016/j.fsigen.2007.08.017. View

13.

Miller M . An emerging paradigm in atherosclerosis: focus on subclinical disease. Postgrad Med. 2009; 121(2):49-59. DOI: 10.3810/pgm.2009.03.1976. View

14.

Li W, Su S, Chen J, Ma H, Xiang M . Emerging roles of fibroblasts in cardiovascular calcification. J Cell Mol Med. 2020; 25(4):1808-1816. PMC: 7882970. DOI: 10.1111/jcmm.16150. View

15.

Messeguer X, Escudero R, Farre D, Nunez O, Martinez J, Alba M . PROMO: detection of known transcription regulatory elements using species-tailored searches. Bioinformatics. 2002; 18(2):333-4. DOI: 10.1093/bioinformatics/18.2.333. View

16.

Xu Z, Taylor J . SNPinfo: integrating GWAS and candidate gene information into functional SNP selection for genetic association studies. Nucleic Acids Res. 2009; 37(Web Server issue):W600-5. PMC: 2703930. DOI: 10.1093/nar/gkp290. View

17.

Dekker M, Waissi F, Silvis M, Bennekom J, Schoneveld A, de Winter R . High levels of osteoprotegerin are associated with coronary artery calcification in patients suspected of a chronic coronary syndrome. Sci Rep. 2021; 11(1):18946. PMC: 8460823. DOI: 10.1038/s41598-021-98177-4. View

18.

Krzanowski M, Krzanowska K, Dumnicka P, Gajda M, Woziwodzka K, Fedak D . Elevated Circulating Osteoprotegerin Levels in the Plasma of Hemodialyzed Patients With Severe Artery Calcification. Ther Apher Dial. 2018; 22(5):519-529. DOI: 10.1111/1744-9987.12681. View

19.

Abdi S, Binbaz R, Mohammed A, Ansari M, Wani K, Amer O . Association of and Gene Polymorphism in Arab Women with and without Osteoporosis. Genes (Basel). 2021; 12(2). PMC: 7910965. DOI: 10.3390/genes12020200. View

20.

Schoppet M, Preissner K, Hofbauer L . RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function. Arterioscler Thromb Vasc Biol. 2002; 22(4):549-53. DOI: 10.1161/01.atv.0000012303.37971.da. View